India Globalization Capital (NYSE MKT: IGC) recently named Craig Cheifetz, M.D. as an advisor to assist the company with its clinical trials in microbiology, immunology, neuroscience and biotechnology. IGC CEO Ram Mukunda stated in a news release that the company looks forward to Dr. Cheifetz’s contributions as IGC moves forward in the development of unique cannabis combination therapies. “The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.”
To view the full article, visit http://nnw.fm/BzQ0Q
About India Globalization Capital, Inc.
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
About CannabisNewsBreaks
CannabisNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of CannabisNewsWire (CNW). NNB keeps you up-to-date on active US Public Companies complementary to CNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
Please see full disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, CO
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
